Evidence map›Paper›PMID 26444073›Full record

SynthesisBiological psychiatry2016

A Meta-Analysis of Mismatch Negativity in Schizophrenia: From Clinical Risk to Disease Specificity and Progression.

Molly A Erickson, Abigail Ruffle, James M Gold

Open access · greenAbstract readMeta-Analysis
PubMed Full text at PMC Publisher
In one paragraph

Synthesis in Biological psychiatry, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 196 papers, 9 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
196citing papers in PubMed, 9 pooled it
12.4field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

196 citing papers in PubMed, 9 syntheses or guidelines pooled it, 421 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Pooled it
  8. Pooled it
  9. Pooled it
  10. Trial
  11. Trial
  12. Trial
  13. Acute effects of ΔPsychopharmacology · 2022
    Trial
  14. Reliability of mismatch negativity event-related potentials in a multisite, traveling subjects study.Clinical neurophysiology : official journal of the International Federation of Clinical Neurophysiology · 2020
    Trial
  15. Effects of clonidine on MMN and P3a amplitude in schizophrenia patients on stable medication.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2019
    Trial
  16. Trial
  17. Trial
  18. Neurophysiological Effects of Bitopertin in Schizophrenia.Journal of clinical psychopharmacology · 2017
    Trial
  19. Trial
  20. Mismatch negativity matures in adolescence and without sensitivity to microglial depletion.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2026
    Article

136 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 1 institution in 1 country.

Molly A EricksonMaryland Psychiatric Research Center, University of Maryland School of Medicine, Baltimore, Maryland. Electronic address: merickson@mprc.umaryland.edu.
Abigail RuffleMaryland Psychiatric Research Center, University of Maryland School of Medicine, Baltimore, Maryland.
James M GoldMaryland Psychiatric Research Center, University of Maryland School of Medicine, Baltimore, Maryland.
University of Maryland, Baltimore · US

Funding

Cognitive Neuroscience of Attention in SchizophreniaR01MH065034 · NIMH · UNIVERSITY OF MARYLAND BALTIMORE · PI James M. Gold, STEVEN J LUCK · 2001 to 2026
$13.9M
Multidisciplinary Schizophrenia Research TrainingT32MH067533 · NIMH · UNIVERSITY OF MARYLAND BALTIMORE · PI CARPENTER, WILLIAM T., ELMER, GREGORY I · 2004 to 2025
$4.3M
NIMH NIH HHS R01 MH065034NIMH NIH HHS T32 MH067533
6 · The paper itself

Abstract

backgroundThe observation that mismatch negativity (MMN) is consistently impaired in schizophrenia has generated considerable interest in the use of this biomarker as an index of disease risk and progression. Despite such enthusiasm, a number of issues remain unresolved regarding the nature of MMN impairment. The present study expands upon an earlier meta-analysis of MMN impairment in schizophrenia by examining impairment across a range of clinical presentations, as well as across experimental parameters.

methodsOne hundred one samples of schizophrenia patients were included in the present study, including first-episode (n = 13), chronic (n = 13), and mixed-stage (n = 75) samples. Additionally, MMN was examined in three related conditions: bipolar disorder (n = 9), unaffected first-degree relatives (n = 8), and clinical high risk (n = 16).

resultsWe found that MMN impairment 1) likely reflects a vulnerability to disease progression in clinical high-risk populations rather than a genetic risk for the condition; 2) is largely unrelated to duration of illness after the first few years of illness, indicating that impairment is not progressive throughout the life span; 3) is present in bipolar disorder, albeit to a lesser degree than in schizophrenia; and 4) is not modulated by experimental parameters such as magnitude of change between standard and deviant tones or frequency of deviant tones but may be modulated by attentional demands.

conclusionsSuch findings lay the foundation for a better understanding of the nature of MMN impairment in schizophrenia, as well as its potential as a clinically useful biomarker.

Indexed as

Disease ProgressionAdultBipolar DisorderEvoked PotentialsFemaleHumansMaleSchizophreniaYoung AdultBipolar disorderHigh riskMeta-analysisMismatch negativityProdromalSchizophrenia

Identifiers

PMID26444073
PMCPMC4775447
OpenAlexW2196103100

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.